title: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis.
abstract: OBJECTIVE
  Expression of epidermal growth factor receptor (EGFR) is observed in 50-70% of colorectal carcinoma and is associated with poor prognosis. The aim of this study was to determine the prognostic value of EGFR status before radiotherapy in a group of patients with locally advanced rectal cancer treated with preoperative radiotherapy.
  
  
  METHODS
  Eighty-seven patients were studied retrospectively. Treatment consisted of pelvic radiotherapy, in 50 patients with concomitant chemotherapy and surgical resection. Immunohistochemistry for EGFR was determined at the preradiation biopsy and in the resected specimens. Immunohistochemical analysis for EGFR expression was evaluated according to extension and staining intensity. We defined positive staining (EGFR positive), when extension was 5% or more.
  
  
  RESULTS
  A total of 52 of 87 tumors showed EGFR positive status at biopsy (60%) and EGFR expression was associated neither with clinical tumor stage nor with clinical nodal stage. EGFR positive expression was linked to a lack of pathologic complete response to preoperative radiotherapy (P=0.006). Disease-free survival was lower among patients with EGFR positive status before radiotherapy (P=0.003). In a multivariate analysis EGFR expression at biopsy was a statistically significant predictor of disease-free survival, RR=2.88(1.1-7.8), P=0.036.
  
  
  CONCLUSIONS
  EGFR is expressed in a significant number of rectal tumors. EGFR-positive expression before radiotherapy is an indicator for poor response and low disease-free survival.
authors.affiliation: Department of Radiation Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Giralt
authors.forename: Manuel
authors.initials: M
authors.lastname: de las Heras
authors.forename: Laura
authors.initials: L
authors.lastname: Cerezo
authors.forename: Aranzazu
authors.initials: A
authors.lastname: Eraso
authors.forename: Edurado
authors.initials: E
authors.lastname: Hermosilla
authors.forename: Dolores
authors.initials: D
authors.lastname: Velez
authors.forename: Juan
authors.initials: J
authors.lastname: Lujan
authors.forename: Eloi
authors.initials: E
authors.lastname: Espin
authors.forename: Jose
authors.initials: J
authors.lastname: Rosello
authors.forename: Joaquin
authors.initials: J
authors.lastname: Majó
authors.forename: Sergi
authors.initials: S
authors.lastname: Benavente
authors.forename: Manel
authors.initials: M
authors.lastname: Armengol
authors.forename: I
authors.initials: I
authors.lastname: de Torres
mesh_terms: D000368:Aged; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D012004:Rectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D066246:ErbB Receptors